The protein Nipah virus uses to latch onto human cells. The disease kills 40 to 75 percent of those infected and has no approved treatment.

A growth signal receptor, mutated in many lung cancers and overproduced in brain tumours, and a target of both antibody and small-molecule drugs.

A surface protein tumours use to switch off the T cells attacking them. Four antibodies that block it are approved.

The shared working part of a large family of enzymes that tag proteins for destruction, accounting for about a fifth of what a cell deliberately destroys.

Results from the GEM x Adaptyv RBX1 Binder Design Competition.

Experimental validation results for 1,196 protein designs targeting the deadly Nipah virus, yielding 111 binders (28 single-digit nM) with associated developability metrics.

To validate BoltzGen in its initial preprint release, 422 designed proteins were experimentally tested against 14 distinct targets.